choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Votrient

Votrient Newsletter
  • Reviewing RCC Treatment Choices After Progression With IO/TKI 27 Mar 2025 22:27 GMT

    … axitinib and tivozanib. Pazopanib [Votrient], cabozantinib, and lenvatinib are … other targets that these pills inhibit. When we … , et al. Optimizing treatment of renal cell carcinoma … pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer …

  • January - March 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) 05 Mar 2025 21:57 GMT

    … Counseling Information,” and “Medication Guide,”  sections of the … Methylphenidate Methylphenidate hydrochloride Drug interaction between … ) Sutent (sunitinib malate) Votrient (pazopanib) Zaltrap (ziv- … Example: Inlyta labeling FDA determined that no …

  • Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation 28 Jan 2025 23:28 GMT

    … release from the drug’s developer, Intensity … trial have been obtained from the FDA, Health Canada, the European Medicines … consisting of either pazopanib (Votrient) tablets, trabectedin (Yondelis … Additionally, grade 3 treatment-related adverse events (TRAEs …

  • FDA Approves New Formulation of Pazopanib Tablets in RCC, Sarcoma 05 Dec 2024 21:57 GMT

    … multicenter, double-blind, phase 3 trial (NCT00387764).4 A total of … of the phase 3 VEG110727 trial (NCT00753688). Patients were randomly assigned … ;tinyurl.com/bdcm87ec FDA approves Votrient® for treatment of patients with certain …

  • USFDA gives nod to Eugia Pharma’s generic drug to treat kidney cancer 05 Dec 2024 11:20 GMT

    … from the US Food & Drug Administration (USFDA) to manufacture and … reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. “The … mg is indicated for the treatment of adults with Advanced Renal …

  • Aurobindo Pharma wins USFDA approval for generic cancer drug 05 Dec 2024 11:13 GMT

    … pm. The generic drug is bioequivalent to Novartis Pharmaceuticals’ Votrient Tablets and is … . Aurobindo plans to launch the medication in the fourth quarter of … company develops and commercialises generic pharmaceuticals across seven therapeutic areas in …

  • Votrient dosage 23 Oct 2024 23:14 GMT

    … taking pills or consult your doctor. Your doctor will likely advise taking Votrient … During treatment, your doctor will monitor the effects of Votrient. If the drug is … have during Votrient treatment. Also, tell them about all the medications and supplements …

  • Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer 01 Oct 2024 20:39 GMT

    … phase 1/2 clinical trial for patients with metastatic kidney … of Oncology and Medicine and Director of Network Clinical Trials at Roswell … (brand name Votrient), which is FDA-approved for the treatment of metastatic clear …

  • Votrient side effects: What you should know 16 Sep 2024 16:53 GMT

    … (FDA) approves a drug, it tracks and reviews side effects of the medication … common side effect of Votrient in clinical trials. Votrient can cause a loss … or skin during treatment with Votrient, talk with your doctor. They may recommend …

  • Combo Treatment Doubles Survival for Patients With Advanced Kidney Cancer 17 Sep 2024 10:31 GMT

    … Votrient) and bevacizumab (Avastin). Pazopanib is from a class of cancer drugs … grow. In prior trials that led to pazopanib … trial, which involved 51 patients, found that combining pazopanib treatment … for powerful immunotherapy cancer medicines, but George…

Satisfied with the content?

Continue to create your account.